Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Anticancer drug development: the grand challenges

Abstract

Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Acknowledgements

The author would like to acknowledge the members of Ortho Biotech Oncology Research and Development who helped formulate the concepts contained herein, and those who reviewed the manuscript and offered helpful comments.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hait, W. Anticancer drug development: the grand challenges. Nat Rev Drug Discov 9, 253–254 (2010). https://doi.org/10.1038/nrd3144

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3144

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research